0001179110-20-011996.txt : 20201216 0001179110-20-011996.hdr.sgml : 20201216 20201216163015 ACCESSION NUMBER: 0001179110-20-011996 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201214 FILED AS OF DATE: 20201216 DATE AS OF CHANGE: 20201216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wright Richard M. CENTRAL INDEX KEY: 0001646423 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 201392746 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0306 4 2020-12-14 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001646423 Wright Richard M. C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 0 1 0 0 Sr. VP & CCO Common Stock 2020-12-14 4 M 0 11457 9.0165 A 11665 D Common Stock 2020-12-14 4 S 0 11457 18.6065 D 208 D Common Stock 2020-12-14 4 M 0 9375 2.78 A 9583 D Common Stock 2020-12-14 4 S 0 9375 18.6065 D 208 D Incentive Stock Option 9.0165 2020-12-14 4 M 0 11457 0.00 D 2028-06-13 Common Stock 11457 6876 D Incentive Stock Option 2.78 2020-12-14 4 M 0 9375 0.00 D 2029-06-19 Common Stock 9375 20625 D On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock. This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019. 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Samuel B. Martin, attorney in fact for Richard M. Wright 2020-12-16